Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AnaptysBio, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with a confirmed clinical diagnosis of eosinophilic asthma
History of diagnosis of eosinophilic asthma
Severe asthma diagnosed according to the Global Initiative for Asthma (GINA) 2016
Body mass index (BMI) of 18 to 38 kilograms per squared meters (kg/m\^2) (inclusive) and total body weight \> 50 kg (110 pounds)
Women of childbearing potential must have a negative serum pregnancy test at screening and be willing to use highly effective methods of contraception throughout the study
Male participants must be willing to use effective methods of contraception during the entire study period.
Participant must be on high dose inhaled corticosteroids (ICS) plus long-acting beta-2-agonists (LABA)
Willing and able to comply with the study protocol requirements
Have the ability to read and understand the study procedures and can communicate meaningfully with the Investigator and staff
You may not be if
Have concomitant medical condition(s) which may interfere with the Investigator's ability to evaluate the participant's response to the investigational product (IP)
Have experienced severe life threatening anaphylactic reactions
Have received any IP within a period of 3 months or 5 half lives of an IP
Have received high dose systemic corticosteroids
Have received treatment with biologics, such as mepolizumab or omalizumab, within 3 months or 5 half lives (whichever is longer) before screening
Abnormal electrocardiogram (ECG) assessment at screening
Uncontrolled hypertension, or acute ischemic cardiovascular diseases
If female, is pregnant or lactating, or intend to become pregnant during the study period
History (or suspected history) of alcohol or substance abuse within 2 years before screening
Any comorbidity that the Investigator believes is a contraindication to study participation
Have any other physical, mental, or medical conditions which, in the opinion of the Investigator, make study participation inadvisable or could confound study assessments
Planned surgery during the study or 30 days before screening
History of malignancy within 5 years, except non melanoma skin cancer which has been fully treated with no current active disease
Clareo Health | Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
